Agenda
Symposium (90 minutes)
- Introduction (5 minutes)
- Current Landscape of Long-Acting ART for Treatment and Prevention of HIV (15 minutes)
- Incorporating Long-Acting ART for Treatment and Prevention Into Clinical Practice (15 minutes)
- Panel Discussion: Strategies to Maximize Uptake (20 minutes)
- Emerging Long-Acting ART Regimens for HIV Prevention and Treatment (10 minutes)
- Panel Discussion: Long-Acting ART in the HIV Armamentarium: What Does the Future Hold? (10 minutes)
- Conclusion and Question and Answer Session (15 minutes)
Meet the Faculty: Extended Question and Answer Session (30 minutes)
Events
Date / Time
Event Details
Faculty
Faculty
Yvonne Gilleece, MB, BCh, BAO
Faculty
Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy
Faculty
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Faculty
Darrell H. S. Tan, MD, FRCPC, PhD
Associate Professor
Division of Infectious Diseases
University of Toronto
Clinician-Scientist
Division of Infectious Diseases
St. Michael's Hospital
Toronto, Canada
Goal Statement
The goal of this activity is to improve the knowledge and competence of HCPs regarding the current and future roles of long-acting antiretroviral regimens in HIV treatment and prevention strategies.
Target Audience
This program is intended for physicians, pharmacists, registered nurses, nurse practitioners, physician associates/physician assistants, and other healthcare professionals who provide care for persons with or at high risk of acquiring HIV infection.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Apply a thorough understanding of available clinical data, practice guidelines, and patient preferences to ensure that long-acting ART is considered as a treatment strategy for patients for whom it may be appropriate
- Integrate strategies to administer long-acting ART, support patient adherence to dosing visits, and monitor its efficacy and safety in clinical settings
- Appraise the role of long-acting PrEP in HIV prevention strategies based on considerations including efficacy, safety, and patient preferences
Accreditation
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-129-L02-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.